Lung Cancer
Conference Coverage
Glimmer of promise for nivolumab in neoadjuvant NSCLC therapy
COPENHAGEN – Checkpoint inhibitors have shown good efficacy for treatment of advanced NSCLC, but use in the neoadjuvant setting is still...
Article
Clinicians call for expanded pulmonary palliative care
Conference Coverage
NSCLC survival comparable with accelerated and conventional RT
BOSTON – Patients with stage II or III non–small-cell lung cancer with comorbidities that make them poor candidates for surgery or chemotherapy...
News
Racial gaps persist in lung cancer trial enrollment
Key clinical point: Elderly women, blacks, Asians, Pacific Islanders, and Hispanics are all still underrepresented in lung cancer clinical trials...
News
Recommendations for Cancer Moonshot overlook a few issues, YSC says
News
FDA modifies dosage regimen for nivolumab
Conference Coverage
Low caregiver self-care linked with depression, anxiety
Key clinical point: There is increased anxiety and depression among family caregivers who do not take care of themselves. Major finding: Worse...
News
New anticancer drugs linked to increased costs, life expectancy
From the Journals
Whole brain radiotherapy not beneficial for NSCLC metastasis
Whole brain radiotherapy provided no clinically significant benefit for most patients with metastatic non–small-cell lung cancer.
From the Journals
Pneumonitis with nivolumab treatment shows common radiographic patterns
Among 20 cancer patients treated with this PD-1 inhibitor who developed pneumonitis, cryptogenic organizing pneumonia was seen in 13.
Conference Coverage
Cancer trends shifting in HIV-positive patients
Key clinical point: HIV-infected persons in North America have roughly a 1 in 25 cumulative lifetime risk of developing lung cancer, Kaposi’s...